CAPTURE 2

(Carotid RX Acculink/RX Accunet Post-Approval Trial to Uncover Unanticipated or Rare Events)

The CAPTURE 2 trial is a post-marketing trial open to all patients in whom the RX ACCUNET and/or RX ACCULINK systems are appropriate. Guidant Endovascular Solutions is sponsoring this trial. The trial will be conducted at 400 U. S centers with open ended enrollment. The purpose of the study is to provide an ongoing post-market surveillance mechanism to document clinical outcomes. This study will help ensure Medicare reimbursement to those patients enrolled in the trial.

Contant Info Principal Investigator: Suhail Dohad, MD Study Coordinator: : Maria Thottam, BS Contact number: 310.275.9551

Clinical Trials

Congestive Heart Failure

FUSION II

PROCLAIM

RED HF

Heart Failure Devices

PEGASUS CRT

OPTIMIZER III

Acute Coronary Syndrome

Horizons

Triton – TIMI 38

Coronary Artery Disease

Crescendo

Transcendence PCI

TACT

Carotid Artery Disease

CAPTURE 2

CT Projects

DXV406

DXV301